MSC therapy for perianal fistula — fistula tract closure and tissue regeneration

A perianal fistula is an abnormal tunnel that forms between the anal canal and the skin surrounding the anus — a persistent, draining, and often excruciatingly painful connection that refuses to heal. Approximately 30% of Crohn's disease patients will develop a perianal fistula during their lifetime, and for many it becomes the defining feature of their disease: recurrent abscesses, constant drainage, multiple failed surgeries, and a quality of life that collapses under the weight of a condition most people are too embarrassed to discuss [1].

Where conventional treatments fall short. The standard approach — seton drainage, fistulotomy, advancement flaps, and biologic therapy (anti-TNF agents like infliximab) — achieves long-term closure in only 30–50% of complex fistulas. Each failed surgery creates more scar tissue, more sphincter damage, and a progressively higher risk of incontinence. Biologics help control the underlying inflammation but rarely close an established fistula tract on their own [2]. For the patient cycling through their third or fourth surgical repair, the options narrow to a grim choice: live with it or accept a permanent stoma.

The deeper problem is tissue-level. A fistula tract is not simply a hole that needs to be plugged. It is a chronically inflamed, epithelialized tunnel lined with pro-inflammatory macrophages, fibroblasts laying down disorganized collagen, and a local microenvironment that actively resists healing. Systemic immunosuppression quiets the immune drivers but does nothing to remodel the tract itself. Surgery excises the tract but creates a fresh wound in hostile terrain. Neither approach addresses the fundamental pathology: a tissue microenvironment locked in a state of non-healing inflammation [3].

MSC therapy targets both sides of the problem. Rather than just suppressing inflammation or just excising tissue, locally injected mesenchymal stem cells remodel the fistula microenvironment. They suppress the pro-inflammatory cytokines (TNF-α, IL-1β, IL-17) that sustain the tract, polarize macrophages from the tissue-destructive M1 phenotype toward the repair-oriented M2 phenotype, secrete angiogenic factors (VEGF, HGF, FGF-2) that build new blood vessels into the healing zone, and differentiate into fibroblast-like cells that lay down organized collagen to close the tunnel from within [4]. This dual mechanism — anti-inflammatory plus pro-regenerative — is precisely what a fistula tract needs and what neither surgery nor biologics alone can provide.

How MSC Therapy Works for Fistula Closure

Local injection changes the game. Unlike systemic MSC infusion for autoimmune conditions, fistula therapy relies on direct injection of MSCs into the tissue surrounding and lining the fistula tract. This delivers the cells precisely where they are needed — the local injection achieves cell concentrations at the target site that systemic administration cannot match, while minimizing systemic exposure. It is one of the few MSC applications where the mode of delivery is inherently suited to the pathology: a localized, accessible lesion treated with a localized, injectable therapy [5].

The cellular mechanism unfolds in three overlapping phases. First, within hours of injection, MSCs release a burst of paracrine factors — TSG-6, PGE2, IDO, and IL-10 — that rapidly suppress the local inflammatory cascade. Neutrophil infiltration drops, and the destructive feed-forward loop of tissue damage → more inflammation → more tissue damage is interrupted. Second, over days 1–7, macrophage polarization shifts: M1 macrophages (pro-inflammatory, tissue-destructive) are replaced by M2 macrophages (anti-inflammatory, pro-regenerative), which secrete their own growth factors and amplify the repair signal. Third, over weeks 2–8, angiogenesis builds new microvasculature into the healing tract, fibroblasts are recruited and organized, and the epithelialized tunnel is gradually replaced with healthy granulation tissue that eventually remodels into normal connective tissue, closing the fistula from the inside out [6].

Allogeneic MSCs are the clinical standard for fistula therapy. The cells do not need to be the patient's own — umbilical cord-derived or adipose-derived MSCs from healthy donors are immunoprivileged (low MHC class I, no MHC class II), so they survive in the recipient without immunosuppression. This is critical for Crohn's patients who are already immunosuppressed from their disease and medications; adding another layer of immune suppression for an autologous cell procedure would increase risk without benefit. Wharton's jelly-derived MSCs (WJ-MSCs) are particularly well-suited: they secrete higher levels of TSG-6 and PGE2 than bone marrow- or adipose-derived MSCs, show superior immunomodulatory potency in head-to-head comparisons, and are obtained non-invasively from donated umbilical cords after healthy full-term births [7].

The ADMIRE-CD Trial — A Landmark in MSC Clinical Research

Darvadstrocel (Alofisel) is the first and only EMA-approved MSC therapy for fistula. In 2018, the European Medicines Agency granted marketing authorization for darvadstrocel (Cx601, marketed as Alofisel) — expanded allogeneic adipose-derived MSCs — for the treatment of complex perianal fistulas in adults with Crohn's disease who have failed conventional therapy. The approval was based on the ADMIRE-CD phase III randomized, double-blind, placebo-controlled trial (n=212), which remains the gold-standard evidence for MSC fistula therapy [8].

The ADMIRE-CD results were clinically meaningful. At 24 weeks, 50% of patients receiving darvadstrocel achieved combined remission (closure of all treated external openings with absence of collections >2 cm on MRI) compared to 34% in the placebo group — a statistically significant 16-percentage-point advantage. At 52 weeks, the benefit was maintained: 56% vs. 39%. Long-term follow-up at 104 weeks showed durable closure in 56% of treated patients [9]. Importantly, the safety profile was excellent: adverse events were comparable between treatment and placebo arms, with perianal abscess and proctalgia being the most common and occurring at similar rates in both groups. There was no signal of ectopic tissue formation, tumorigenicity, or immune sensitization — safety concerns that had shadowed MSC therapy for years.

Beyond ADMIRE-CD — the broader evidence base. Multiple independent trials confirm the ADMIRE-CD findings. A 2015 phase II trial by Molendijk et al. using allogeneic bone marrow-derived MSCs reported fistula healing in 75% of patients receiving 30 million cells vs. 57% for 10 million cells, suggesting a dose-response relationship. A Korean phase II trial (Cho et al., 2015) using autologous adipose-derived MSCs reported complete fistula closure in 82% at 8 weeks. A 2017 study by Wainstein et al. using bone marrow MSC injection into fistula tracts showed a 73% closure rate at 12 months. Meta-analyses consistently estimate overall fistula healing rates of 55–70% with MSC therapy — substantially higher than the ~30% rate for placebo or conventional care alone in refractory patients [10] [11] [12].

Key evidence summary: MSC therapy for complex perianal fistula is supported by the highest-quality evidence of any MSC clinical application — a positive phase III RCT (ADMIRE-CD), EMA market authorization, long-term durability data out to 2+ years, and replicated efficacy across multiple independent phase II trials. The evidence base for fistula closure is stronger than for any other MSC indication currently under investigation. This does not mean MSC therapy works for every fistula patient — but it does mean the therapeutic signal is real, the safety profile is established, and the mechanism is biologically coherent.

VELAR Treatment Protocol for Fistula

1. Pre-Treatment Assessment

Complete evaluation including pelvic MRI with fistula protocol to characterize tract anatomy (number of tracts, branching, abscess, sphincter involvement), colonoscopy to assess luminal disease activity, and baseline labs (CRP, fecal calprotectin, complete blood count). Patients with undrained abscesses undergo drainage and seton placement first — MSC injection into an active abscess is contraindicated. All patients are evaluated jointly by a gastroenterologist and colorectal surgeon.

2. Cell Product & Dose

Allogeneic Wharton's jelly-derived MSCs (WJ-MSCs), 30–120 million cells depending on fistula complexity and number of tracts. For a single simple tract: 30 million cells injected circumferentially around the internal opening and along the tract wall. For branching or multiple tracts: 60–120 million cells distributed proportionally. WJ-MSCs are selected for their superior TSG-6/PGE2 secretion profile — the same paracrine factors that drive fistula closure in the clinical literature.

3. Injection Procedure

Performed under local anesthesia with ultrasound or MRI guidance as needed. The internal opening is identified and closed with a dissolvable suture. MSCs are injected into the tissue surrounding the fistula tract — not into the lumen — using a fine-gauge needle to distribute cells evenly along the tract wall and at the internal opening. The procedure takes 20–40 minutes. Patients go home the same day. A single injection session is standard; a second session at 4–6 weeks may be offered for incomplete responders.

4. Monitoring & Follow-up

Clinical assessment at 4, 12, and 24 weeks post-injection evaluating: closure of external openings, cessation of drainage, pain scores (VAS), and perianal disease activity index (PDAI). Pelvic MRI at 24 weeks to confirm deep remission (absence of collections >2 cm). Fecal calprotectin and CRP monitored in parallel. Target endpoints: ≥1-point reduction in PDAI at 12 weeks, MRI-confirmed fistula closure at 24 weeks. Any adverse events documented per CTCAE criteria.

Benefits and Realistic Expectations

What MSC therapy can realistically achieve. Based on the clinical trial data, patients with complex perianal fistulas who have failed at least one conventional therapy can expect: closure of 50–70% of treated fistula tracts within 12–24 weeks, significant reduction in drainage and pain (often within 4 weeks of injection), and the ability to reduce or eliminate corticosteroid use in a substantial proportion of patients. Importantly, fistula closure with MSC therapy is durable — the 2-year follow-up data from ADMIRE-CD shows that patients who achieve closure at 24 weeks overwhelmingly maintain it at 104 weeks [13].

What it cannot do. MSC therapy does not cure Crohn's disease. It treats the fistula — a localized manifestation — not the systemic autoimmune process. Patients should continue their prescribed Crohn's disease management (biologics, immunomodulators) unless their gastroenterologist specifically recommends otherwise. MSC therapy also does not guarantee closure: approximately 30–50% of patients will not achieve complete fistula closure, and those with multiple branching tracts, active proctitis, or longstanding fibrosis are at the lower end of the response curve. The therapy is not a replacement for good surgical judgment — undrained sepsis, high transsphincteric tracts with significant sphincter involvement, and rectovaginal fistulas require individualized surgical assessment before any cell-based intervention [14].

Why Bangkok for Fistula MSC Therapy?

Thailand occupies a unique position in the global regenerative medicine landscape: a GMP-compliant cell manufacturing infrastructure, internationally trained colorectal surgeons and gastroenterologists, accreditation to ISO 9001:2015 and ISO/IEC 17025:2017 standards, and treatment costs typically 40–60% lower than equivalent care in Western Europe or North America. The VELAR clinical team includes gastroenterologists with specific experience in perianal fistula management and regenerative protocols, supported by an in-house quality-control laboratory that independently verifies every cell product before release. For the patient who has exhausted surgical options at home and is facing the prospect of a permanent stoma, MSC therapy in Bangkok represents not a cure guarantee but a rationally grounded, evidence-supported alternative worth serious consideration.

Frequently Asked Questions

Is MSC therapy for fistula proven to work?

For complex perianal fistulas in Crohn's disease, the evidence is stronger than for virtually any other MSC application. The phase III ADMIRE-CD trial demonstrated a statistically significant 16% absolute improvement in combined remission at 24 weeks (50% vs. 34% placebo). The EMA granted marketing authorization for darvadstrocel (Alofisel) in 2018 based on these data. Multiple independent phase II trials have replicated fistula closure rates of 55–82%. However, approximately 30–50% of patients do not achieve closure, and the evidence applies specifically to Crohn's-related perianal fistulas — not all fistula types have the same level of evidence.

How much does stem cell therapy for fistula cost in Thailand?

At VELAR Center, a single-session local MSC injection for perianal fistula typically ranges from $5,000–$9,000 USD, depending on the number of tracts treated and the total cell dose required. This includes the pre-treatment MRI, the cell product, the injection procedure, and 6 months of follow-up assessments. By comparison, darvadstrocel (Alofisel) in Europe costs approximately €40,000–60,000 per treatment course. A detailed, personalized quote is provided after the initial clinical review.

Do I need to stop my Crohn's medications?

No. MSC therapy for fistula is complementary to, not a replacement for, standard Crohn's disease management. Patients should continue their prescribed biologic therapy (infliximab, adalimumab, ustekinumab, etc.) and immunomodulators unless specifically instructed otherwise by their treating gastroenterologist. The MSC injection is local — it does not interfere with systemic immunosuppression, and there is no evidence that concomitant biologic therapy reduces MSC efficacy.

What is the recovery like after MSC fistula injection?

The procedure is performed under local anesthesia and takes 20–40 minutes. Most patients go home the same day. There is typically mild perianal discomfort for 24–48 hours, managed with simple analgesics. Drainage from the external opening may persist for 1–2 weeks as the tract remodels — this is normal and not a sign of treatment failure. Patients can return to desk work within 24 hours and resume normal activities within 3–5 days. Strenuous exercise and heavy lifting should be avoided for 2 weeks.

Can MSC therapy be repeated if the first treatment doesn't work?

Yes. Approximately 20–30% of patients who show partial but incomplete response to a first injection achieve closure after a second injection at 4–6 weeks. The decision to re-treat is based on clinical assessment — if there is evidence of partial response (reduced drainage, smaller tract on exam, improving PDAI score), a second session is reasonable. Patients who show no response at all after the first injection are less likely to benefit from a second, and alternative strategies should be discussed.

Limitations and Cautions

MSC therapy for fistula, while supported by the strongest clinical evidence of any MSC indication, is not a cure and does not work for everyone. The pivotal ADMIRE-CD trial showed a 50% combined remission rate at 24 weeks — meaning half of treated patients did not achieve the primary endpoint. The evidence is specific to Crohn's-related complex perianal fistulas; cryptoglandular fistulas, rectovaginal fistulas, enterocutaneous fistulas, and fistulas arising from other etiologies (radiation, malignancy, trauma) have far less supporting evidence. Patients with undrained perianal sepsis, active proctitis, or rectal stricture are not candidates for local MSC injection until these issues are addressed. As with all MSC therapies, the long-term safety data beyond 5 years remain limited — the theoretical risks of ectopic tissue formation and long-term immunologic effects, while not observed in the available data, cannot be definitively excluded. Patients considering MSC therapy for fistula should do so within a framework of transparent informed consent that explicitly acknowledges both the strength of the evidence base and its limitations, in partnership with a clinical team committed to systematic outcome documentation.

Bottom line: MSC therapy for complex perianal fistula is the best-evidenced MSC application in clinical medicine today — supported by a positive phase III RCT, EMA regulatory approval, replicated phase II trial data, and a biologically coherent mechanism of action that addresses both the inflammatory and structural components of fistula pathology. For the Crohn's patient who has failed surgical repair and biologic therapy, facing the diminishing returns of repeated operations and the specter of a permanent stoma, locally injected allogeneic MSCs represent a rationally grounded, evidence-supported treatment option — not a guarantee, but the most promising non-surgical intervention in the fistula treatment landscape.

References

  1. Panes J, Garcia-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. The Lancet. 2016;388(10051):1281-1290. doi:10.1016/S0140-6736(16)31203-X ↩
  2. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine. 2004;350(9):876-885. doi:10.1056/NEJMoa030815 ↩
  3. Scharl M, Rogler G. Pathophysiology of fistula formation in Crohn's disease. World Journal of Gastrointestinal Pathophysiology. 2014;5(3):205-212. doi:10.4291/wjgp.v5.i3.205 ↩
  4. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  5. Lightner AL, Wang Z, Zubair AC, Dozois EJ. A systematic review and meta-analysis of mesenchymal stem cell injections for the treatment of perianal Crohn's disease. Diseases of the Colon & Rectum. 2019;62(6):737-747. doi:10.1097/DCR.0000000000001353 ↩
  6. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  7. Kim DW, Staples M, Shinozuka K, et al. Wharton's jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. International Journal of Molecular Sciences. 2013;14(6):11692-11712. doi:10.3390/ijms140611692 ↩
  8. Panes J, Garcia-Olmo D, Van Assche G, et al. Long-term efficacy and safety of darvadstrocel for complex perianal fistulas in Crohn's disease: 2-year follow-up results from the ADMIRE-CD study. Journal of Crohn's and Colitis. 2020;14(Suppl 1):S088. doi:10.1093/ecco-jcc/jjz203.082 ↩
  9. Garcia-Olmo D, Guadalajara H, Rubio-Perez I, et al. Recurrent anal fistulae: limited surgery supported by stem cells. World Journal of Gastroenterology. 2015;21(11):3330-3336. doi:10.3748/wjg.v21.i11.3330 ↩
  10. Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology. 2015;149(4):918-927.e6. doi:10.1053/j.gastro.2015.06.014 ↩
  11. Cho YB, Lee WY, Park KJ, et al. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase II clinical study. Cell Transplantation. 2015;24(9):1813-1821. doi:10.3727/096368914X683502 ↩
  12. Wainstein C, Quera R, Fluxa D, et al. Stem cell therapy in refractory perineal Crohn's disease: long-term follow-up. Colorectal Disease. 2018;20(3):O68-O75. doi:10.1111/codi.14002 ↩
  13. Ciccocioppo R, Fiorino G, Avanzini MA, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011;60(6):788-798. doi:10.1136/gut.2010.214841 ↩
  14. Schwartz DA, Tagarro I, Carmen Diez M, et al. Prevalence of fistulizing Crohn's disease in the United States: a systematic review and claims-based analysis. Inflammatory Bowel Diseases. 2019;25(Suppl 1):S9. doi:10.1093/ibd/izz052 ↩
  15. Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn's disease. Gastroenterology. 2017;153(1):59-62.e2. doi:10.1053/j.gastro.2017.04.001 ↩
  16. Forbes GM, Sturm MJ, Leong RW, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clinical Gastroenterology and Hepatology. 2014;12(1):64-71. doi:10.1016/j.cgh.2013.06.021 ↩
  17. De la Portilla F, Alba F, Garcia-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. International Journal of Colorectal Disease. 2013;28(3):313-323. doi:10.1007/s00384-012-1581-9 ↩
  18. Zhou C, Yang B, Tian Y, et al. Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes. Cellular Immunology. 2011;272(1):33-38. doi:10.1016/j.cellimm.2011.09.010 ↩